Abstract
Vascular complications are a leading cause of blindness, end-stage renal failure, a variety of neuropathies and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. There is a growing body of evidence that formation and accumulation of advanced glycation end products (AGEs) progress during normal aging, and at an extremely accelerated rate in diabetes, thus being involved in the pathogenesis of diabetic vascular complications. Furthermore, the interaction by AGEs of their receptor, RAGE, activates down-stream signaling and evokes inflammatory responses in vascular wall cells. Therefore, inhibition of AGE formation or blockade of the RAGE signaling may be a promising target for therapeutic intervention to prevent diabetic vascular complications. This review discusses the molecular mechanisms of diabetic retinopathy, especially focusing on the AGE-RAGE system. Several types of inhibitors of the AGE-RAGE system and their therapeutic implications are also reviewed here.
Keywords: Diabetic retinopathy, advanced glycation end products (AGEs), oxidative stress, receptor for advanced, glycation end products, pigment epithelium-derived factor (PEDF)
Current Drug Discovery Technologies
Title: Advanced Glycation End Products (AGEs) and their Receptor (RAGE) System in Diabetic Retinopathy
Volume: 3 Issue: 1
Author(s): Sho-ichi Yamagishi, Kazuo Nakamura and Takanori Matsui
Affiliation:
Keywords: Diabetic retinopathy, advanced glycation end products (AGEs), oxidative stress, receptor for advanced, glycation end products, pigment epithelium-derived factor (PEDF)
Abstract: Vascular complications are a leading cause of blindness, end-stage renal failure, a variety of neuropathies and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. There is a growing body of evidence that formation and accumulation of advanced glycation end products (AGEs) progress during normal aging, and at an extremely accelerated rate in diabetes, thus being involved in the pathogenesis of diabetic vascular complications. Furthermore, the interaction by AGEs of their receptor, RAGE, activates down-stream signaling and evokes inflammatory responses in vascular wall cells. Therefore, inhibition of AGE formation or blockade of the RAGE signaling may be a promising target for therapeutic intervention to prevent diabetic vascular complications. This review discusses the molecular mechanisms of diabetic retinopathy, especially focusing on the AGE-RAGE system. Several types of inhibitors of the AGE-RAGE system and their therapeutic implications are also reviewed here.
Export Options
About this article
Cite this article as:
Yamagishi Sho-ichi, Nakamura Kazuo and Matsui Takanori, Advanced Glycation End Products (AGEs) and their Receptor (RAGE) System in Diabetic Retinopathy, Current Drug Discovery Technologies 2006; 3 (1) . https://dx.doi.org/10.2174/157016306776637555
DOI https://dx.doi.org/10.2174/157016306776637555 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroprotection by Natural Polyphenols: Molecular Mechanisms
Central Nervous System Agents in Medicinal Chemistry Defining Cell Identity by Comprehensive Gene Expression Profiling
Current Medicinal Chemistry Recent Patents on Genes and Gene Sequences Useful for Developing Breast Cancer Detection Systems
Recent Patents on DNA & Gene Sequences Conditionally Replicating Adenoviruses for Cancer Treatment
Current Cancer Drug Targets Antiproliferative Activity of microRNA-125a and its Molecular Targets
MicroRNA Molecular Mechanism of Anti-tumor Effect by Triptolide in Hematological Malignancies
Current Signal Transduction Therapy Sirtuins: Novel Players in Male Reproductive Health
Current Medicinal Chemistry The SCF-type E3 Ubiquitin Ligases as Cancer Targets
Current Cancer Drug Targets Novel Aspects of Neuronal Differentiation In Vitro and Monitoring with Advanced Biosensor Tools
Current Medicinal Chemistry Silimarin and Cancer
Anti-Cancer Agents in Medicinal Chemistry Compounds From Celastraceae Targeting Cancer Pathways and Their Potential Application in Head and Neck Squamous Cell Carcinoma: A Review
Current Genomics The p53-Estrogen Receptor Loop in Cancer
Current Molecular Medicine Ocular Toxicities in Cancer Therapy: Still Overlooked
Current Cancer Therapy Reviews The Development of MetAP-2 Inhibitors in Cancer Treatment
Current Medicinal Chemistry Enjoy the Silence: The Story of let-7 MicroRNA and Cancer
Current Genomics Regulatory Roles of Amino Acids in Immune Response
Current Rheumatology Reviews The Immunohistochemical Assessment of HPV Related Adenocarcinoma: Pathologic and Clinical Prognostic Significance
Current Pharmaceutical Design 1,2,3-Triazine Scaffold as a Potent Biologically Active Moiety: A Mini Review
Mini-Reviews in Medicinal Chemistry Photosensitizer Nanoparticles for Photodynamic Therapy
Current Bioactive Compounds Gene Expression Profiles Induced by Amphetamine and Phencyclidine; Novel Targets for the Treatment of Drug Psychosis and Schizophrenia
Medicinal Chemistry Reviews - Online (Discontinued)